Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 21
Filtrar
1.
N Engl J Med ; 376(4): 330-341, 2017 01 26.
Artículo en Inglés | MEDLINE | ID: mdl-25830322

RESUMEN

BACKGROUND: The worst Ebola virus disease (EVD) outbreak in history has resulted in more than 28,000 cases and 11,000 deaths. We present the final results of two phase 1 trials of an attenuated, replication-competent, recombinant vesicular stomatitis virus (rVSV)-based vaccine candidate designed to prevent EVD. METHODS: We conducted two phase 1, placebo-controlled, double-blind, dose-escalation trials of an rVSV-based vaccine candidate expressing the glycoprotein of a Zaire strain of Ebola virus (ZEBOV). A total of 39 adults at each site (78 participants in all) were consecutively enrolled into groups of 13. At each site, volunteers received one of three doses of the rVSV-ZEBOV vaccine (3 million plaque-forming units [PFU], 20 million PFU, or 100 million PFU) or placebo. Volunteers at one of the sites received a second dose at day 28. Safety and immunogenicity were assessed. RESULTS: The most common adverse events were injection-site pain, fatigue, myalgia, and headache. Transient rVSV viremia was noted in all the vaccine recipients after dose 1. The rates of adverse events and viremia were lower after the second dose than after the first dose. By day 28, all the vaccine recipients had seroconversion as assessed by an enzyme-linked immunosorbent assay (ELISA) against the glycoprotein of the ZEBOV-Kikwit strain. At day 28, geometric mean titers of antibodies against ZEBOV glycoprotein were higher in the groups that received 20 million PFU or 100 million PFU than in the group that received 3 million PFU, as assessed by ELISA and by pseudovirion neutralization assay. A second dose at 28 days after dose 1 significantly increased antibody titers at day 56, but the effect was diminished at 6 months. CONCLUSIONS: This Ebola vaccine candidate elicited anti-Ebola antibody responses. After vaccination, rVSV viremia occurred frequently but was transient. These results support further evaluation of the vaccine dose of 20 million PFU for preexposure prophylaxis and suggest that a second dose may boost antibody responses. (Funded by the National Institutes of Health and others; rVSV∆G-ZEBOV-GP ClinicalTrials.gov numbers, NCT02269423 and NCT02280408 .).


Asunto(s)
Vacunas contra el Virus del Ébola/inmunología , Ebolavirus/inmunología , Fiebre Hemorrágica Ebola/prevención & control , Adulto , Anticuerpos Antivirales/sangre , Método Doble Ciego , Vacunas contra el Virus del Ébola/administración & dosificación , Vacunas contra el Virus del Ébola/efectos adversos , Ebolavirus/genética , Ebolavirus/aislamiento & purificación , Ensayo de Inmunoadsorción Enzimática , Femenino , Fiebre Hemorrágica Ebola/inmunología , Humanos , Masculino , Persona de Mediana Edad , Proteínas Recombinantes , Seroconversión , Vacunas Atenuadas/inmunología , Virus de la Estomatitis Vesicular Indiana , Proteínas del Envoltorio Viral/aislamiento & purificación , Viremia
2.
N Engl J Med ; 368(6): 524-32, 2013 Feb 07.
Artículo en Inglés | MEDLINE | ID: mdl-23388004

RESUMEN

BACKGROUND: There is a need for a simple and efficacious treatment for cutaneous leishmaniasis with an acceptable side-effect profile. METHODS: We conducted a randomized, vehicle-controlled phase 3 trial of topical treatments containing 15% paromomycin, with and without 0.5% gentamicin, for cutaneous leishmaniasis caused by Leishmania major in Tunisia. We randomly assigned 375 patients with one to five ulcerative lesions from cutaneous leishmaniasis to receive a cream containing 15% paromomycin-0.5% gentamicin (called WR 279,396), 15% paromomycin alone, or vehicle control (with the same base as the other two creams but containing neither paromomycin nor gentamicin). Each lesion was treated once daily for 20 days. The primary end point was the cure of the index lesion. Cure was defined as at least 50% reduction in the size of the index lesion by 42 days, complete reepithelialization by 98 days, and absence of relapse by the end of the trial (168 days). Any withdrawal from the trial was considered a treatment failure. RESULTS: The rate of cure of the index lesion was 81% (95% confidence interval [CI], 73 to 87) for paromomycin-gentamicin, 82% (95% CI, 74 to 87) for paromomycin alone, and 58% (95% CI, 50 to 67) for vehicle control (P<0.001 for each treatment group vs. the vehicle-control group). Cure of the index lesion was accompanied by cure of all other lesions except in five patients, one in each of the paromomycin groups and three in the vehicle-control group. Mild-to-moderate application-site reactions were more frequent in the paromomycin groups than in the vehicle-control group. CONCLUSIONS: This trial provides evidence of the efficacy of paromomycin-gentamicin and paromomycin alone for ulcerative L. major disease. (Funded by the Department of the Army; ClinicalTrials.gov number, NCT00606580.).


Asunto(s)
Gentamicinas/administración & dosificación , Leishmaniasis Cutánea/tratamiento farmacológico , Paromomicina/administración & dosificación , Administración Tópica , Adolescente , Adulto , Anciano , Niño , Preescolar , Quimioterapia Combinada , Femenino , Gentamicinas/efectos adversos , Humanos , Análisis de Intención de Tratar , Masculino , Persona de Mediana Edad , Pomadas , Paromomicina/efectos adversos , Adulto Joven
3.
Antimicrob Agents Chemother ; 57(10): 4809-15, 2013 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-23877689

RESUMEN

This study evaluated the pharmacokinetics of topical creams containing 15% paromomycin ("paromomycin alone") and 15% paromomycin plus 0.5% gentamicin (WR 279,396) in patients with cutaneous leishmaniasis. The investigational creams were applied topically to all lesions once daily for 20 days. Plasma samples were analyzed for simultaneous quantitation of paromomycin and gentamicin isomers and total gentamicin. Pharmacokinetic parameters for gentamicin could not be calculated because detectable levels were rarely evident. After one application, the paromomycin area under the concentration-time curve from 0 to 24 h (AUC0-24) was 2,180 ± 2,621 ng · h/ml (mean ± standard deviation [SD]) for the paromomycin-alone group and 975.6 ± 1,078 ng · h/ml for the WR 279,396 group. After 20 days of application, the paromomycin AUC0-24 and maximum concentration of drug (Cmax) were 5 to 6 times greater than those on day 1 for both treatment groups. For the paromomycin-alone group, the AUC0-24 was 8,575 ± 7,268 ng · h/ml and the Cmax was 1,000 ± 750 ng/ml, compared with 6,037 ± 3,956 ng · h/ml and 660 ± 486 ng/ml for the WR 279,396 group, respectively. Possibly due to large intersubject variability, no differences (P ≥ 0.05) in the AUC0-24 or Cmax were noted between treatment or between sites on day 1 or 20. The percentage of dose absorbed on day 20 was 12.0% ± 6.26% and 9.68% ± 6.05% for paromomycin alone and WR 279,396, respectively. Paromomycin concentrations in plasma after 20 days of application were 5 to 9% of those after intramuscular administration of 15 mg/kg of body weight/day to adults for the systemic treatment of visceral leishmaniasis. Effective topical treatment of cutaneous leishmaniasis appears to be possible with limited paromomycin and gentamicin systemic absorption, thus avoiding drug accumulation and toxicity. (The work described here has been registered at ClinicalTrials.gov under registration no. NCT01032382 and NCT01083576.).


Asunto(s)
Gentamicinas/farmacocinética , Gentamicinas/uso terapéutico , Leishmaniasis Cutánea/tratamiento farmacológico , Paromomicina/farmacocinética , Paromomicina/uso terapéutico , Adulto , Niño , Femenino , Gentamicinas/administración & dosificación , Gentamicinas/sangre , Humanos , Leishmaniasis Cutánea/sangre , Masculino , Paromomicina/administración & dosificación , Paromomicina/sangre
4.
Bioorg Med Chem ; 19(5): 1692-701, 2011 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-21316974

RESUMEN

A series of 15-membered azalide urea and thiourea derivatives has been synthesized and evaluated for their in vitro antimalarial activity against chloroquine-sensitive (D6), chloroquine/pyremethamine resistant (W2) and multidrug resistant (TM91C235) strains of Plasmodium falciparum. We have developed an effective automated synthetic strategy for the rapid synthesis of urea/thiourea libraries of a macrolide scaffold. Compounds have been synthesized using a solution phase strategy with overall yields of 50-80%. Most of the synthesized compounds had inhibitory effects. The top 10 compounds were 30-65 times more potent than azithromycin, an azalide with antimalarial activity, against all three strains.


Asunto(s)
Antimaláricos/síntesis química , Plasmodium falciparum/efectos de los fármacos , Tiourea/síntesis química , Urea/síntesis química , Antimaláricos/química , Antimaláricos/farmacología , Automatización , Azitromicina/farmacología , Resistencia a Múltiples Medicamentos , Concentración 50 Inhibidora , Macrólidos/farmacología , Estructura Molecular , Relación Estructura-Actividad , Tiourea/química , Tiourea/farmacología , Urea/química , Urea/farmacología
5.
J Med Chem ; 51(7): 2261-6, 2008 Apr 10.
Artículo en Inglés | MEDLINE | ID: mdl-18330976

RESUMEN

Of 17 prepared 1,2,4,5-tetraoxacyclohexanes stable to reductive and acidic conditions, 3 of them were more active than artemisinin against CQ and MFQ resistant strain TM91C235 and all compounds were more active in vitro against W2 than against D6 strain. In vivo, amines 10 and 11a cured all mice at higher doses with MCD < or = 37.5 (mg/kg)/day. Triol 13 was exceptionally active against melanoma (LOX IMVI) and ovarian cancer (IGROV1), both with LC 50 = 60 nM.


Asunto(s)
Antimaláricos/síntesis química , Antimaláricos/farmacología , Peróxidos/química , Plasmodium falciparum/efectos de los fármacos , Tetraoxanos/síntesis química , Tetraoxanos/farmacología , Animales , Antimaláricos/química , Antineoplásicos/síntesis química , Antineoplásicos/química , Antineoplásicos/farmacología , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Ensayos de Selección de Medicamentos Antitumorales , Humanos , Estructura Molecular , Pruebas de Sensibilidad Parasitaria , Estereoisomerismo , Relación Estructura-Actividad , Tetraoxanos/química
6.
Drug Metab Dispos ; 36(2): 380-5, 2008 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-18006651

RESUMEN

Phenoxypropoxybiguanides, such as PS-15, are antimalarial prodrugs analogous to the relationship of proguanil and its active metabolite cycloguanil. Unlike cycloguanil, however, WR99210, the active metabolite of PS-15, has retained in vitro potency against newly emerging antifolate-resistant malaria parasites. Recently, in vitro metabolism of a new series of phenoxypropoxybiguanide analogs has examined the production of the active triazine metabolites by human liver microsomes. The purpose of this investigation was to elucidate the primary cytochrome P450 isoforms involved in the production of active metabolites in the current lead candidate. By using expressed human recombinant isoform preparations, specific chemical inhibitors, and isoform-specific inhibitory antibodies, the primary cytochrome P450 isoforms involved in the in vitro metabolic activation of JPC-2056 were elucidated. Unlike proguanil, which is metabolized primarily by CYP2C19, the results indicate that CYP3A4 plays a more important role in the metabolism of both PS-15 and JPC-2056. Whereas CYP2D6 appears to play a major role in the metabolism of PS-15 to WR99210, it appears less important in the conversion of JPC-2056 to JPC-2067. These results are encouraging, considering the prominence of CYP2C19 and CYP2D6 polymorphisms in certain populations at risk for contracting malaria, because the current clinical prodrug candidate from this series may be less dependent on these enzymes for metabolic activation.


Asunto(s)
Antimaláricos/metabolismo , Sistema Enzimático del Citocromo P-450/metabolismo , Profármacos/metabolismo , Proguanil/análogos & derivados , Proguanil/metabolismo , Anticuerpos Monoclonales/farmacología , Inhibidores Enzimáticos del Citocromo P-450 , Sistema Enzimático del Citocromo P-450/genética , Humanos , Microsomas Hepáticos/metabolismo , Isoformas de Proteínas/antagonistas & inhibidores , Isoformas de Proteínas/genética , Isoformas de Proteínas/metabolismo , Proteínas Recombinantes/metabolismo , Triazinas/metabolismo
7.
Bioorg Med Chem ; 16(14): 7039-45, 2008 Jul 15.
Artículo en Inglés | MEDLINE | ID: mdl-18550377

RESUMEN

Eleven new tetraoxanes possessing cholic acid-derived carrier and isopropylidene moiety were synthesized and were tested in vitro and in vivo. In vitro screening revealed that nine of them were more potent against CQ-resistant W2 than CQ-susceptible D6 strain and that two of them were equally or more potent than artemisinin and mefloquine against multi-drug resistant TM91C235 strain. Amine 8 cured all mice at the dose of 160mg/kg/day, while the anilide 9 exhibited MCD

Asunto(s)
Antimaláricos/síntesis química , Tetraoxanos/síntesis química , Tetraoxanos/farmacología , Acetona , Animales , Artemisininas , Evaluación Preclínica de Medicamentos , Resistencia a Múltiples Medicamentos , Mefloquina , Ratones , Plasmodium falciparum/efectos de los fármacos
8.
Bioorg Med Chem ; 16(8): 4626-51, 2008 Apr 15.
Artículo en Inglés | MEDLINE | ID: mdl-18321710

RESUMEN

Tryprostatin A is an inhibitor of breast cancer resistance protein, consequently a series of structure-activity studies on the cell cycle inhibitory effects of tryprostatin A analogues as potential antitumor antimitotic agents have been carried out. These analogues were assayed for their growth inhibition properties and their ability to perturb the cell cycle in tsFT210 cells. SAR studies resulted in the identification of the essential structural features required for cytotoxic activity. The absolute configuration L-Tyr-L-pro in the diketopiperazine ring along with the presence of the 6-methoxy substituent on the indole moiety of 1 was shown to be essential for dual inhibition of topoisomerase II and tubulin polymerization. Biological evaluation also indicated the presence of the 2-isoprenyl moiety on the indole scaffold of 1 was essential for potent inhibition of cell proliferation. Substitution of the indole N(a)-H in 1 with various alkyl or aryl groups, incorporation of various L-amino acids into the diketopiperazine ring in place of L-proline, and substitution of the 6-methoxy group in 1 with other functionality provided active analogues. The nature of the substituents present on the indole N(a)-H or the indole C-2 position influenced the mechanism of action of these analogues. Analogues 68 (IC(50)=10 microM) and 67 (IC(50)=19 microM) were 7-fold and 3.5-fold more potent, respectively, than 1 (IC(50)=68 microM) in the inhibition of the growth of tsFT210 cells. Diastereomer-2 of tryprostatin B 8 was a potent inhibitor of the growth of three human carcinoma cell lines: H520 (IC(50)=11.9 microM), MCF-7 (IC(50)=17.0 microM) and PC-3 (IC(50)=11.1 microM) and was equipotent with etoposide, a clinically used anticancer agent. Isothiocyanate analogue 71 and 6-azido analogue 72 were as potent as 1 in the tsFT210 cell proliferation and may be useful tools in labeling BCRP.


Asunto(s)
Neoplasias de la Mama/metabolismo , Neoplasias de la Mama/patología , Resistencia a Antineoplásicos/efectos de los fármacos , Alcaloides Indólicos/síntesis química , Alcaloides Indólicos/farmacología , Piperazinas/síntesis química , Piperazinas/farmacología , Antineoplásicos/síntesis química , Antineoplásicos/química , Antineoplásicos/farmacología , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , ADN-Topoisomerasas de Tipo II/metabolismo , Inhibidores Enzimáticos/síntesis química , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/farmacología , Humanos , Alcaloides Indólicos/química , Estructura Molecular , Piperazinas/química , Relación Estructura-Actividad , Inhibidores de Topoisomerasa II , Tubulina (Proteína)/metabolismo
9.
Birth Defects Res B Dev Reprod Toxicol ; 83(4): 435-45, 2008 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-18636509

RESUMEN

BACKGROUND: Injectable artesunate (AS) can cause fetal death and teratogenic effects in animals at levels below the human therapeutic dose. Similar toxicity has also been found for oral artemisinins in various animal species, but has not been found in humans. METHODS: Studies on tissue distribution (5 mg/kg) and toxicokinetics (TK, 30 mg/kg x 3) were conducted in pregnant (GD11-13) and non-pregnant rats. RESULTS: TK profiles of AS showed that the two groups of rats were similar after a single AS dose but were significantly different after multiple doses. Following a daily dose for 3 days, no change in AS concentration was found in the pregnant animals, but a significant concentration decline was seen in the non-pregnant rats on day 3. In addition, a higher conversion rate of AS to dihydroartemisinin (DHA) was detected in the pregnant rats after either single or multiple doses compared to non-pregnant controls. The ratios of AUC(DHA)/AUC(AS) were 0.99-1.02 for the pregnant rats and 0.42-0.48 for non-pregnant animals, resulting in a total AUC(DHA D1-3) that was about 3.7-fold higher in pregnant rats (15,049 ng.h/ml) than in non-pregnant rats (4,015 ng.h/ml). Furthermore, the tissue/blood partition coefficients demonstrated that the level of radiolabeled AS that was distributed into uterus, placenta, and ovary was 2-4-fold higher than in blood. CONCLUSIONS: TK data showed that unchanged AS and DHA in the blood of pregnant rats were 1.53- and 3.74-fold, respectively, higher than those of non-pregnant animals, which all likely relate to the severe embryotoxicity of AS, even with a low-dosage regimen in pregnant animals.


Asunto(s)
Artemisininas/farmacocinética , Artemisininas/toxicidad , Embrión de Mamíferos/efectos de los fármacos , Animales , Artemisininas/administración & dosificación , Artemisininas/sangre , Artemisininas/química , Artesunato , Autorradiografía , Femenino , Inyecciones Intravenosas , Embarazo , Efectos Tardíos de la Exposición Prenatal/inducido químicamente , Ratas , Ratas Sprague-Dawley , Distribución Tisular
10.
J Med Chem ; 50(21): 5118-27, 2007 Oct 18.
Artículo en Inglés | MEDLINE | ID: mdl-17887664

RESUMEN

The synthesis of deoxycholic acid (DCA)- and cholic acid (CA)-derived mixed tetraoxanes revealed that N-(2-dimethylamino)ethyl derivatives are potent antimalarials in vitro and in vivo. The tetraoxanes presented in this paper are dual inhibitors: besides curing mice in vivo without observed toxic effects, they kill cancer cell lines at very low concentrations. For example, DCA and CA derivatives 16 and 25 cured 3/5 (160 mg/kg/day) and 2/5 (40 mg/kg/day, MTD >960 mg/kg), respectively, and they were extremely active against melanoma LOX IMVI cancer, LC50 = 22 nM and 69 nM, respectively.


Asunto(s)
Antimaláricos/síntesis química , Antineoplásicos/síntesis química , Ácido Desoxicólico/análogos & derivados , Ácido Desoxicólico/síntesis química , Tetraoxanos/síntesis química , Animales , Antimaláricos/metabolismo , Antimaláricos/farmacología , Antineoplásicos/metabolismo , Antineoplásicos/farmacología , Línea Celular Tumoral , Cristalografía por Rayos X , Ciclohexanos/síntesis química , Ciclohexanos/metabolismo , Ciclohexanos/farmacología , Ácido Desoxicólico/metabolismo , Ácido Desoxicólico/farmacología , Resistencia a Medicamentos , Ensayos de Selección de Medicamentos Antitumorales , Humanos , Malaria/tratamiento farmacológico , Ratones , Microsomas/metabolismo , Plasmodium berghei , Plasmodium falciparum/efectos de los fármacos , Estereoisomerismo , Relación Estructura-Actividad , Tetraoxanos/metabolismo , Tetraoxanos/farmacología
11.
J Med Chem ; 49(13): 3790-9, 2006 Jun 29.
Artículo en Inglés | MEDLINE | ID: mdl-16789736

RESUMEN

Mixed tetraoxanes 5a and 13 synthesized from cholic acid and 4-oxocyclohexanecarboxylic acid were as active as artemisinin against chloroquine-susceptible, chloroquine-resistant, and multidrug-resistant Plasmodium falciparum strains (IC50, IC90). Most active 13 is metabolically stable in in vitro metabolism studies. In vivo studies on tetraoxanes with a C(4' ') methyl group afforded compound 15, which cured 4/5 mice at 600 and 200 mg.kg-1.day-1, and 2/5 mice at 50 mg.kg-1.day-1, showing no toxic effects. Tetraoxane 19 was an extremely active antiproliferative with LC50 of 17 nM and maximum tolerated dose of 400 mg/kg. In Fe(II)-induced scission of tetraoxane antimalarials only RO* radicals were detected by EPR experiments. This finding and the indication of Fe(IV)=O species led us to propose that RO* radicals are probably capable of inducing the parasite's death. Our results suggest that C radicals are possibly not the only lethal species derived from peroxide prodrug antimalarials, as currently believed.


Asunto(s)
Antimaláricos/síntesis química , Compuestos Ferrosos/química , Tetraoxanos/síntesis química , Animales , Antimaláricos/química , Antimaláricos/farmacología , Antineoplásicos/síntesis química , Antineoplásicos/química , Antineoplásicos/farmacología , Línea Celular Tumoral , Ensayos de Selección de Medicamentos Antitumorales , Espectroscopía de Resonancia por Spin del Electrón , Radicales Libres/química , Humanos , Técnicas In Vitro , Ratones , Microsomas Hepáticos/metabolismo , Estructura Molecular , Plasmodium falciparum/efectos de los fármacos , Relación Estructura-Actividad , Tetraoxanos/química , Tetraoxanos/farmacología
12.
Comb Chem High Throughput Screen ; 8(1): 89-98, 2005 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-15720200

RESUMEN

The high level of attrition of drugs in clinical development has led pharmaceutical companies to increase the efficiency of their lead identification and development through techniques such as combinatorial chemistry and high-throughput (HTP) screening. Since the major reasons for clinical drug candidate failure other than efficacy are pharmacokinetics and toxicity, attention has been focused on assessing properties such as metabolic stability, drug-drug interactions (DDI), and absorption earlier in the drug discovery process. Animal studies are simply too labor-intensive and expensive to use for evaluating every hit, so it has been necessary to develop and implement higher throughput in vitro ADME screens to manage the large number of compounds of interest. The antimalarial drug development program at the Walter Reed Army Institute of Research, Division of Experimental Therapeutics (WRAIR/ET) has adopted this paradigm in its search for a long-term prophylactic for the prevention of malaria. The overarching goal of this program is to develop new, long half-life, orally bioavailable compounds with potent intrinsic activity against liver- and blood-stage parasites. From the WRAIR HTP antimalarial screen, numerous compounds are regularly identified with potent activity. These hits are now immediately evaluated using a panel of in vitro ADME screens to identify and predict compounds that will meet our specific treatment criteria. In this review, the WRAIR ADME screening program for antimalarial drugs is described as well as how we have implemented it to predict the ADME properties of small molecule for the identification of promising drug candidates.


Asunto(s)
Antimaláricos/química , Animales , Antimaláricos/farmacología , Línea Celular , Perros , Diseño de Fármacos , Interacciones Farmacológicas , Humanos , Absorción Intestinal , Espectrometría de Masas
13.
J Med Chem ; 45(8): 1559-62, 2002 Apr 11.
Artículo en Inglés | MEDLINE | ID: mdl-11931609

RESUMEN

Tryprostatin A 1 and B 2 are indole alkaloid-based fungal products that act in the G2/M phase of the cell cycle. Tryprostatin A and B as well as their two enantiomers and four diastereomers have been synthesized via a common strategy. As a measure of cytotoxicity, these eight stereoisomers were assayed for their growth inhibitory properties in human breast, prostate, and lung cancer cell lines. The ability of the tryprostatins and the tryprostatin stereoisomers to induce topoisomerase II-mediated DNA relaxation or to inhibit tubulin polymerization was also examined. Although none of the stereoisomers were significantly active in topoisomerase II- or tubulin-based assays, ds2-try B 11 was found to exhibit a cytotoxicity profile more potent than etoposide 3 in the human cancer cell lines examined. In addition, ds2-try B 11 is comprised of an L-tryptophan derivative coupled to a D-proline moiety, the latter stereochemistry of which may enhance the activity of 11 and potential analogues in vivo.


Asunto(s)
Antineoplásicos/farmacología , Alcaloides Indólicos/farmacología , Piperazinas/farmacología , Antineoplásicos/química , Biopolímeros , División Celular/efectos de los fármacos , ADN/química , ADN-Topoisomerasas de Tipo II/química , Ensayos de Selección de Medicamentos Antitumorales , Humanos , Alcaloides Indólicos/química , Piperazinas/química , Estereoisomerismo , Relación Estructura-Actividad , Tubulina (Proteína)/química , Células Tumorales Cultivadas
14.
J Med Chem ; 55(3): 1389-401, 2012 Feb 09.
Artículo en Inglés | MEDLINE | ID: mdl-22148880

RESUMEN

Novel classes of antimalarial drugs are needed due to emerging drug resistance. Azithromycin, the first macrolide investigated for malaria treatment and prophylaxis, failed as a single agent and thus novel analogues were envisaged as the next generation with improved activity. We synthesized 42 new 9a-N substituted 15-membered azalides with amide and amine functionalities via simple and inexpensive chemical procedures using easily available building blocks. These compounds exhibited marked advances over azithromycin in vitro in terms of potency against Plasmodium falciparum (over 100-fold) and high selectivity for the parasite and were characterized by moderate oral bioavailability in vivo. Two amines and one amide derivative showed improved in vivo potency in comparison to azithromycin when tested in a mouse efficacy model. Results obtained for compound 6u, including improved in vitro potency, good pharmacokinetic parameters, and in vivo efficacy higher than azithromycin and comparable to chloroquine, warrant its further development for malaria treatment and prophylaxis.


Asunto(s)
Aminoquinolinas/síntesis química , Antimaláricos/síntesis química , Eritromicina/análogos & derivados , Macrólidos/síntesis química , Amidas/síntesis química , Amidas/farmacocinética , Amidas/farmacología , Aminas/síntesis química , Aminas/farmacocinética , Aminas/farmacología , Aminoquinolinas/farmacocinética , Aminoquinolinas/farmacología , Animales , Antimaláricos/farmacocinética , Antimaláricos/farmacología , Azitromicina/farmacología , Línea Celular Tumoral , Resistencia a Medicamentos , Eritromicina/síntesis química , Eritromicina/farmacocinética , Eritromicina/farmacología , Humanos , Macrólidos/farmacocinética , Macrólidos/farmacología , Malaria/tratamiento farmacológico , Masculino , Ratones , Microsomas Hepáticos/metabolismo , Pruebas de Sensibilidad Parasitaria , Plasmodium berghei , Plasmodium falciparum/efectos de los fármacos , Ratas , Relación Estructura-Actividad
15.
J Med Chem ; 54(10): 3595-605, 2011 May 26.
Artículo en Inglés | MEDLINE | ID: mdl-21476508

RESUMEN

Azithromycin, a first member of the azalide family of macrolides, while having substantial antimalarial activity, failed as a single agent for malaria prophylaxis. In this paper we present the first analogue campaign to identify more potent compounds from this class. Ureas and thioureas of 15-membered azalides, N''-substituted 9a-(N'-carbamoyl-ß-aminoethyl), 9a-(N'-thiocarbamoyl-ß-aminoethyl), 9a-[N'-(ß-cyanoethyl)-N'-(carbamoyl-ß-aminoethyl)], 9a-[N'-(ß-cyanoethyl)-N'-(thiocarbamoyl-ß-aminoethyl)], 9a-{N'-[ß-(ethoxycarbonyl)ethyl]-N'(carbamoyl-ß-aminoethyl)}, and 9a-[N'-(ß-amidoethyl)-N'-(carbamoyl-ß-aminoethyl)] of 9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin A, were synthesized and their biological properties evaluated. The results obtained indicate a substantial improvement of the in vitro activity against P. falciparum (up to 88 times over azithromycin), particularly for compounds containing both sugars on the macrocyclic ring and aromatic moiety on 9a-position. The improved in vitro activity was not confirmed in the mouse model, likely due to an increase in lipophilicity of these analogues leading to a higher volume of distribution. Overall, with increased in vitro activity, promising PK properties, and modest in vivo efficacy, this series of molecules represents a good starting platform for the design of novel antimalarial azalides.


Asunto(s)
Antimaláricos/síntesis química , Macrólidos/química , Tiourea/química , Urea/química , Animales , Antimaláricos/química , Azitromicina/análogos & derivados , Química Farmacéutica/métodos , Diseño de Fármacos , Humanos , Concentración 50 Inhibidora , Ratones , Modelos Químicos , Plasmodium falciparum/metabolismo , Relación Estructura-Actividad
16.
J Med Chem ; 51(19): 6216-9, 2008 Oct 09.
Artículo en Inglés | MEDLINE | ID: mdl-18774792

RESUMEN

The synthesis of the chimeric molecules consisting of two pharmacophores, tetraoxane and 7-chloro-4-aminoquinoline, is reported. The tetraoxanes 2, 4, and 8 show relatively potent in vitro antimalarial activities, with IC90 values for the Plasmodium falciparum strain W2 of 2.26, 12.44, and 10.74 nM, respectively. In addition, two compounds, 2 and 4, cured mice in a modified Thompson test for antimalarial blood stage activity, with a minimum curative dose of 80 mg/kg, a minimum active dose of 20 mg/kg/day, and a maximum tolerated dose of >960 mg/kg.


Asunto(s)
Aminoquinolinas/química , Antimaláricos/síntesis química , Antimaláricos/farmacología , Malaria/tratamiento farmacológico , Plasmodium falciparum/efectos de los fármacos , Tetraoxanos/química , Animales , Antimaláricos/química , Sitios de Unión , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Malaria/sangre , Malaria/parasitología , Dosis Máxima Tolerada , Ratones , Estructura Molecular , Pruebas de Sensibilidad Parasitaria , Estereoisomerismo , Relación Estructura-Actividad
17.
J Med Chem ; 51(15): 4388-91, 2008 Aug 14.
Artículo en Inglés | MEDLINE | ID: mdl-18637666

RESUMEN

We report on the initial result of the coupling of 4-amino-7-chloroquinoline with steroidal and adamantane constituents to provide small molecules with excellent in vitro antimalarial activities (IC90 (W2) down to 6.74 nM). The same entities also inhibit the botulinum neurotoxin serotype A light chain metalloprotease at low micromolar levels (7-31 microM). Interestingly, structural features imparting increased antimalarial activity also provide increased metalloprotease inhibition, thus allowing for simultaneous compound optimizations against distinct targets.


Asunto(s)
Aminoquinolinas/química , Aminoquinolinas/farmacología , Toxinas Botulínicas Tipo A/antagonistas & inhibidores , Cloroquina/farmacología , Resistencia a Medicamentos/efectos de los fármacos , Plasmodium falciparum/efectos de los fármacos , Animales , Toxinas Botulínicas Tipo A/metabolismo , Estructura Molecular , Relación Estructura-Actividad
18.
Antimicrob Agents Chemother ; 51(8): 2898-904, 2007 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-17562804

RESUMEN

Pyrroloquinazolinediamine (PQD) derivatives such as tetra-acetamide PQD (PQD-A4) and bis-ethylcarbamyl PQD (PQD-BE) were much safer (with therapeutic indices of 80 and 32, respectively) than their parent compound, PQD (therapeutic index, 10). Further evaluation of PQD-A4 and PQD-BE in single and multiple pharmacokinetic (PK) studies as well as corresponding toxicity studies was conducted with rats. PQD-A4 could be converted to two intermediate metabolites (monoacetamide PQD and bisacetamide PQD) first and then to the final metabolite, PQD, while PQD-BE was directly hydrolyzed to PQD without precursor and intermediate metabolites. Maximum tolerant doses showed that PQD-A4 and PQD-BE have only 1/12 and 1/6, respectively, of the toxicity of PQD after a single oral dose. Compared to the area under the concentration-time curve for PQD alone (2,965 ng.h/ml), values measured in animals treated with PQD-A4 and PQD-BE were one-third (1,047 ng.h/ml) and one-half (1,381 ng.h/ml) as high, respectively, after an equimolar dosage, suggesting that PQD was the only agent to induce the toxicity. Similar results were also shown in multiple treatments; PQD-A4 and PQD-BE generated two-fifths and three-fifths, respectively, of PQD concentrations, with 8.8-fold and 3.8-fold safety margins, respectively, over the parent drug. PK data indicated that the bioavailability of oral PQD-A4 was greatly limited at high dose levels, that PQD-A4 was slowly converted to PQD via a sequential three-step process of conversion, and that PQD-A4 was significantly less toxic than the one-step hydrolysis drug, PQD-BE. It was concluded that the slow and smaller release of PQD was the main reason for the reduction in toxicity and that the active intermediate metabolites can still maintain antimalarial potency. Therefore, the candidate with multiple-step hydrolysis of PQD could be developed as a safer potential agent for malaria treatment.


Asunto(s)
Antimaláricos , Pirroles , Quinazolinas , Administración Oral , Animales , Anorexia/inducido químicamente , Antimaláricos/administración & dosificación , Antimaláricos/efectos adversos , Antimaláricos/metabolismo , Antimaláricos/farmacocinética , Disponibilidad Biológica , Hidrólisis , Masculino , Dosis Máxima Tolerada , Pirroles/administración & dosificación , Pirroles/efectos adversos , Pirroles/metabolismo , Pirroles/farmacocinética , Quinazolinas/administración & dosificación , Quinazolinas/efectos adversos , Quinazolinas/metabolismo , Quinazolinas/farmacocinética , Ratas , Ratas Sprague-Dawley
19.
J Antimicrob Chemother ; 60(4): 811-8, 2007 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-17646199

RESUMEN

OBJECTIVES: To assess the antimalarial pharmacodynamics and pharmacokinetics of the novel dihydrofolate reductase (DHFR) inhibitor, JPC2056 and its principal active metabolite JPC2067 in cynomolgus monkeys using an in vivo-in vitro model. METHODS: In a two-phase crossover design, five cynomolgus monkeys were administered a single dose (20 mg/kg) and multiple doses (20 mg/kg daily for 3 days) of JPC2056. Plasma samples collected from treated monkeys were assessed for in vitro antimalarial activity against Plasmodium falciparum lines having wild-type (D6), double-mutant (K1) and quadruple-mutant (TM90-C2A) DHFR-thymidylate synthase (TS) and a P. falciparum line transformed with a Plasmodium vivax dhfr-ts quadruple-mutant allele (D6-PvDHFR). Plasma JPC2056 and JPC2067 concentrations were measured by LC-mass spectrometry. RESULTS: The mean inhibitory dilution (ID(90)) of monkey plasma at 3 h after drug administration against D6, K1 and TM90-C2A was, respectively, 1253, 585 and 869 after the single-dose regimen and 1613, 1120 and 1396 following the multiple-dose regimen. Less activity was observed with the same monkey plasma samples against the D6-PvDHFR line, with a mean ID(90) of 53 after multiple dosing. Geometric mean plasma concentrations of JPC2056 and JPC2067 at 3 h after drug administration were, respectively, 113 and 12 ng/mL after the single dose and 150 and 17 ng/mL after multiple dosing. The mean elimination half-life of JPC2056 was shorter than its metabolite after both regimens (single dose, 7.3 versus 11.8 h; multiple doses, 6.6 versus 11.1 h). CONCLUSIONS: The high potency of JPC2056 against P. falciparum DHFR-TS quadruple-mutant lines provides optimism for the future development of JPC2056 for the treatment of malaria infections.


Asunto(s)
Antimaláricos/farmacología , Antimaláricos/farmacocinética , Animales , Antimaláricos/administración & dosificación , Antimaláricos/sangre , Atención , Cromatografía Líquida de Alta Presión , Farmacorresistencia Microbiana/genética , Semivida , Macaca fascicularis , Masculino , Espectrometría de Masas , Pruebas de Sensibilidad Parasitaria , Plasma/química , Plasmodium falciparum/efectos de los fármacos , Plasmodium vivax/efectos de los fármacos
20.
Bioorg Med Chem Lett ; 16(21): 5682-6, 2006 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-16908136

RESUMEN

Investigation of a series of 1-phenyl-3-aryl-2-propen-1-ones resulted in the identification of nine inhibitors with submicromolar efficacy against at least one Plasmodium falciparum strain in vitro. These inhibitors were inactive when given orally in a Plasmodium berghei infected mouse model. Significant compound degradation occurred upon their exposure to a liver microsome preparation, suggesting metabolic instability may be responsible for the lack of activity in vivo.


Asunto(s)
Antimaláricos/farmacología , Antimaláricos/farmacocinética , Cetonas/farmacología , Cetonas/farmacocinética , Plasmodium falciparum/efectos de los fármacos , Animales , Malaria Falciparum/tratamiento farmacológico , Ratones , Microsomas Hepáticos/fisiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA